{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progressive+Familial+Intrahepatic+Cholestasis+%28PFIC%29", "query": { "condition": "Progressive Familial Intrahepatic Cholestasis (PFIC)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T12:03:16.616Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02057718", "title": "Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Progressive Familial Intrahepatic Cholestasis (PFIC)" ], "interventions": [ { "name": "LUM001 (Maralixibat)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "12 Months to 18 Years" }, "enrollment_count": 33, "start_date": "2014-03-01", "completion_date": "2020-05-08", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-07-23T12:03:16.616Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057718" }, { "nct_id": "NCT04185363", "title": "An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Progressive Familial Intrahepatic Cholestasis (PFIC)" ], "interventions": [ { "name": "Maralixibat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 84, "start_date": "2020-01-08", "completion_date": "2025-04-23", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-23T12:03:16.616Z", "location_count": 10, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04185363" }, { "nct_id": "NCT03566238", "title": "This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PFIC1", "PFIC2" ], "interventions": [ { "name": "A4250 (odevixibat)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Albireo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Months to 18 Years" }, "enrollment_count": 62, "start_date": "2018-05-16", "completion_date": "2020-07-28", "has_results": true, "last_update_posted_date": "2025-11-28", "last_synced_at": "2026-07-23T12:03:16.616Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03566238" }, { "nct_id": "NCT04483531", "title": "Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Progressive Familial Intrahepatic Cholestasis" ], "interventions": [ { "name": "Odevixibat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Albireo", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2024-03-07", "last_synced_at": "2026-07-23T12:03:16.616Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04483531" }, { "nct_id": "NCT06193928", "title": "Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alagille Syndrome", "Progressive Familial Intrahepatic Cholestasis" ], "interventions": [ { "name": "Livmarli", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 70, "start_date": "2023-09-21", "completion_date": "2030-09-20", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-07-23T12:03:16.616Z", "location_count": 8, "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06193928" }, { "nct_id": "NCT04729751", "title": "A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Progressive Familial Intrahepatic Cholestasis", "Alagille Syndrome", "Cholestatic Liver Disease" ], "interventions": [ { "name": "Maralixibat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Days", "maximum_age": "364 Days", "sex": "ALL", "summary": "0 Days to 364 Days" }, "enrollment_count": 27, "start_date": "2021-09-09", "completion_date": "2024-12-17", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-07-23T12:03:16.616Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729751" }, { "nct_id": "NCT03659916", "title": "Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Progressive Familial Intrahepatic Cholestasis" ], "interventions": [ { "name": "A4250 (odevixibat)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Albireo, an Ipsen Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Months", "maximum_age": "100 Years", "sex": "ALL", "summary": "0 Months to 100 Years" }, "enrollment_count": 116, "start_date": "2018-09-28", "completion_date": "2025-12-02", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-07-23T12:03:16.616Z", "location_count": 11, "location_summary": "Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03659916" }, { "nct_id": "NCT03905330", "title": "A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Progressive Familial Intrahepatic Cholestasis (PFIC)" ], "interventions": [ { "name": "Maralixibat", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mirum Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 93, "start_date": "2019-07-09", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-07-23T12:03:16.616Z", "location_count": 11, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03905330" } ] }